Aflibercept in a Persistent Diabetic Macular Edema Refractory to Previous Ranibizumab Therapy
- 1 June 2022
- journal article
- Published by Kare Publishing in European Archives of Medical Research
- Vol. 38 (2) , 90-95
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- An open-label, one-year, noncomparative study to evaluate the safety and tolerability of intravitreal pegaptanib sodium in patients with diabetic macular edemaClinical Ophthalmology, 2014
- Three-Year Outcomes of Individualized Ranibizumab Treatment in Patients with Diabetic Macular EdemaOphthalmology, 2014
- A 2-Year Prospective Randomized Controlled Trial of Intravitreal Bevacizumab or Laser Therapy (BOLT) in the Management of Diabetic Macular EdemaArchives of Ophthalmology (1950), 2012
- Ranibizumab for Diabetic Macular EdemaOphthalmology, 2012
- Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumabAngiogenesis, 2012
- Changes in Aqueous Concentrations of Various Cytokines After Intravitreal Triamcinolone Versus Bevacizumab for Diabetic Macular EdemaAmerican Journal of Ophthalmology, 2011
- Managing diabetic macular edema: The leading cause of diabetes blindnessWorld Journal of Diabetes, 2011
- Vitreous Levels of Vascular Endothelial Growth Factor and Intercellular Adhesion Molecule 1 Are Related to Diabetic Macular EdemaOphthalmology, 2005
- VEGF-Trap: A VEGF blocker with potent antitumor effectsProceedings of the National Academy of Sciences, 2002
- Photocoagulation for Diabetic Macular EdemaArchives of Ophthalmology (1950), 1985